Post My Press Release

Free Press Release Distribution

Category: Healthcare (Page 1 of 69)

Global Needle-free IV Connectors Market Analysis based on Healthcare Applications 2026

Needle-Free IV Connectors are needleless devices for connecting administration sets, syringes, and IV catheters. Depending on internal characteristic and functioning of the parts, connectors are classified as simple and complex. Simple connectors consist of stationary internal parts, whereas, complex connectors function according to the movement of internal parts. Simple connector’s category holds the majority of the products used in the healthcare delivery. The fluid displacement and fluid pathway are determined by the motion of the internal parts namely mechanical valve, which controls the movement and direction of the fluid in complex connectors. External characteristics such as housing, shape, and color for both the type may or may not be similar. The purpose of using needle-free IV connectors apart from the ease in infusion for both care providers and patients is to reduce the risk of needle-stick injuries among the health care providers and reducing the risk of bacterial and microbial contamination.

Some major players operating in the needle-free IV connectors market are Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CareFusion Corporation, ICU Medical, Inc., Nexus Medical LLC, RyMed Technologies, LLC, and Vygon SA.

Request Sample Copy Of This Research Report:

https://www.coherentmarketinsights.com/insight/request-sample/426

According to the World Health Organization (WHO), annually around 1 million deaths are associated with the improper use of syringes and needles, which can be prevented by using needle-free IV connectors. Harmful diseases namely hepatitis and HIV can spread through improper and reuse of needles and syringes. Unsafe use of injections accounts for 5% of HIV, 40% of Hepatitis C and 32% of Hepatitis B virus infections globally. Although needle stick injuries are uncommon they are a potential problem, which can prove to be serious and are also responsible for causing above mentioned diseases. According to the Centers for Disease Control and Prevention (CDC), needle stick injuries account for around 385,000 among healthcare workers in the U.S annually. The most important goal while employing IV administration sets and needle-free connectors is to reduce the manipulation factor as much as possible. Some of the U.S. Food & Drug Administration (FDA) approved needle-free IV connectors include One-Link, CARESITE, MaxPlus, and Kendall.

The global needle-free IV connectors market was valued at US$ 621.1 million in 2016 and is expected to reach a robust CAGR of 10.3% over the forecast period (2017-2025).

Needle free iv connector market

Rising incidence and prevalence of various chronic diseases and need for treatment is expected to boost the needle-free connectors market

North America accounts for the largest share in the global needle-free connectors market, followed by Europe. This is mainly attributed to the rise in the geriatric population and chronic diseases. According to the Centers for Disease Control and Prevention (CDC), 2016, about half of American adults, that is around 117 million people had one or more chronic health conditions and one in four adults had two or more chronic health conditions. The factors driving the growth of the needle-free IV connectors market includes government investments and funding to improve healthcare infrastructure, awareness in people, and healthcare practitioners. For instance, in 2013, the National Healthcare Safety Network (NHSN) and Center for Disease Control and Prevention (CDC) carried out surveillance methods to identify and track device-associated infections by setting the guidelines for the prevention of central-line associated bloodstream infections. Furthermore, according to the World Health Organization (WHO), in 2014, chronic diseases were the leading cause of mortality in Europe with over one-third of the European population above the age of 15 suffering with a chronic disease and two out of three people near 60 age had at least two chronic conditions.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/426

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Lymphocyte Activation Gene – 3 Protein Market Set for Rapid Growth and Trend, by 2026

Immune checkpoint receptors such as lymphocyte activation gene – 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene – 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene – 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene – 3 protein is associated with T cell exhaustion in which the T cells become desensitized and lose their ability to function.

LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene – 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.

Lymphocyte Activation Gene – 3 Protein Market Drivers

Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene – 3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.

Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date – August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period.

Lymphocyte Activation Gene – 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene – 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.


Lymphocyte Activation Gene – 3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene – 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2027


Lymphocyte Activation Gene 3 Protein Market Taxonomy

The global lymphocyte activation gene – 3 protein market is segmented on the basis of drug, cancer type, and region.


By Drug –

  • BMS-986016 (Relatlimab)
  • IMP321
  • IMP701
  • MGD013
  • Others

By Cancer Type –

  • Breast Cancer
  • Melanoma
  • Solid Tumors
  • Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Compounding Pharmacies Market to Reach US$ 2,479.4 thousand by 2021-End

Future Market Insights (FMI), in its latest report titled “Compounding Pharmacies Market: U.S. Industry Assessment and Forecast; 2015–2021”, has projected the U.S. compounding pharmacies market to expand at a CAGR of 5.7% during the forecast period (2015–2021).

Compounding pharmacies are pharmacies that produce drugs tailored to needs of individual patients, by altering, combining, or mixing active pharmaceutical ingredients of drugs. Compounded drugs are prepared under prescription from physicians. Compounding includes combination of two or more drug ingredients in varied proportions. Most regulatory agencies across the world do not approve compounded medications, and do not verify the safety or effectiveness of compounded drugs. These drugs are usually not reimbursed by pharmaceutical benefit agencies.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-us-978

Compounding pharmacies in the U.S. are estimated to account for market value of US$ 3,262.6 Mn by the end of 2015, and is projected to witness stable growth due to rising demand for personalized medicines from customers.    

The report analyses the U.S compounding pharmacies market in terms of market value (US$ Mn) by product, application and therapeutic area, and provides information regarding market dynamics, value chain, competitive landscape, current trends, market estimations and forecast.

The prime driver for the compounding pharmacies market is medicinal drought. Currently, there’s a shortage of over 300 drugs for various diseases in the U.S. When the need for critical drugs are not met through commercially-available branded equivalents, compounded drugs are sought after. Furthermore, increasing demand for anti-aging products that use custom compounded drugs is a prevalent trend across the globe. Innovative sub-therapeutic areas such as bio-identical hormone replacement therapy are also contributing to growing popularity of compounded drugs. 

On the basis of product type, the U.S. compounding pharmacies market is segmented into oral medication, topical medication, mouth washes, and suppositories.

Oral medications, constituting drugs that can be swallowed, are expected to exhibit stable growth rates ranging from 4.7% to 8.4% over 2015–2021.

Topical medications constitutes skin-application medications. Expected drivers for topical medication include rising popularity of innovative and promising personalized skin creams. Creams are most popular due to ease of preparation and also longer shelf-life. Ease of product composition even after combining two or three APIs customizes the drug and reduces manufacturing cost. Hence, price range varies significantly, i.e., from US$ 100 to 9,000 and above. Creams are mainly used for minimizing scars, skin irritations and other dermatological concerns and reducing pain at location, where oral dosages are not possible.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-us-978

Mouthwashes and suppositories are expected to witness slightly lower growth rates owing to formulation rigidity emerging from regulatory restrictions. Popularity of non-sterile products is projected to increase due to increased product safety regulations imposed by the U.S. FDA.

On the basis of application, the U.S. compounding pharmacies market is segmented into medications for adults, veterinary, children, and geriatric population. Among the different application areas, medication for adults is expected to register highest attractiveness index as compared to other application areas during the forecast period. Medication for adults constitute drugs for critical illnesses such as cardiovascular diseases and cancer. Medications for adults are expected to increase owing to more people adopting compounded drugs, as these can be customized as per needs of individual patients.

On the basis of therapeutic area, the U.S. compounding pharmacies market is segmented into pain management and hormone replacement therapy (HRT). Among the two therapeutic area segments, HRT is expected to register highest CAGR as compared to pain management during the forecast period. HRT is expected to gain popularity owing to increasing awareness across the world due to its various benefits associated with age-defying therapies and products to bettering individual health.

Get Full Report Now @ https://www.futuremarketinsights.com/checkout/978

Key market participants covered in the report include PharMEDium Services, LLC, Institutional Pharmacy Solutions, Cantrell Drug Company, and Triangle Compounding Pharmacies

Global Irritable Bowel Syndrome Treatment Market with present Situation and Forecast To 2026

The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.

Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.

Request Sample Copy Of This Research Report:

https://www.coherentmarketinsights.com/insight/request-sample/506

Market Dynamics

The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.

Market Taxonomy

This report segments the global irritable bowel syndrome treatment market on the basis of drug type, medical condition, and distribution channel. On the basis of drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.

Key features of the study:

This report provides in-depth analysis of irritable bowel syndrome treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global irritable bowel syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Abbott Laboratories*, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., Ironwood Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Irritable Bowel Syndrome Treatment Market

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/506

Detailed Segmentation:

Global Irritable Bowel Syndrome Treatment Market, By Drug Type:

Lubiprostone

Linaclotide

Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:

IBS-Constipation

IBS-Diarrhea

Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:

Hospital Pharmacies

Global Irritable Bowel Syndrome Treatment Market, By Geography:

North America

Europe

Asia-Pacific

Latin America

Middle East

Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Compounding Pharmacies Market Value is Expected to Increase to US$ 2,479.4 thousand by 2021-End

Future Market Insights (FMI), in its latest report titled “Compounding Pharmacies Market: U.S. Industry Assessment and Forecast; 2015–2021”, has projected the U.S. compounding pharmacies market to expand at a CAGR of 5.7% during the forecast period (2015–2021).

Compounding pharmacies are pharmacies that produce drugs tailored to needs of individual patients, by altering, combining, or mixing active pharmaceutical ingredients of drugs. Compounded drugs are prepared under prescription from physicians. Compounding includes combination of two or more drug ingredients in varied proportions. Most regulatory agencies across the world do not approve compounded medications, and do not verify the safety or effectiveness of compounded drugs. These drugs are usually not reimbursed by pharmaceutical benefit agencies.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-us-978

Compounding pharmacies in the U.S. are estimated to account for market value of US$ 3,262.6 Mn by the end of 2015, and is projected to witness stable growth due to rising demand for personalized medicines from customers.    

The report analyses the U.S compounding pharmacies market in terms of market value (US$ Mn) by product, application and therapeutic area, and provides information regarding market dynamics, value chain, competitive landscape, current trends, market estimations and forecast.

The prime driver for the compounding pharmacies market is medicinal drought. Currently, there’s a shortage of over 300 drugs for various diseases in the U.S. When the need for critical drugs are not met through commercially-available branded equivalents, compounded drugs are sought after. Furthermore, increasing demand for anti-aging products that use custom compounded drugs is a prevalent trend across the globe. Innovative sub-therapeutic areas such as bio-identical hormone replacement therapy are also contributing to growing popularity of compounded drugs. 

On the basis of product type, the U.S. compounding pharmacies market is segmented into oral medication, topical medication, mouth washes, and suppositories.

Oral medications, constituting drugs that can be swallowed, are expected to exhibit stable growth rates ranging from 4.7% to 8.4% over 2015–2021.

Topical medications constitutes skin-application medications. Expected drivers for topical medication include rising popularity of innovative and promising personalized skin creams. Creams are most popular due to ease of preparation and also longer shelf-life. Ease of product composition even after combining two or three APIs customizes the drug and reduces manufacturing cost. Hence, price range varies significantly, i.e., from US$ 100 to 9,000 and above. Creams are mainly used for minimizing scars, skin irritations and other dermatological concerns and reducing pain at location, where oral dosages are not possible.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-us-978

Mouthwashes and suppositories are expected to witness slightly lower growth rates owing to formulation rigidity emerging from regulatory restrictions. Popularity of non-sterile products is projected to increase due to increased product safety regulations imposed by the U.S. FDA.

On the basis of application, the U.S. compounding pharmacies market is segmented into medications for adults, veterinary, children, and geriatric population. Among the different application areas, medication for adults is expected to register highest attractiveness index as compared to other application areas during the forecast period. Medication for adults constitute drugs for critical illnesses such as cardiovascular diseases and cancer. Medications for adults are expected to increase owing to more people adopting compounded drugs, as these can be customized as per needs of individual patients.

On the basis of therapeutic area, the U.S. compounding pharmacies market is segmented into pain management and hormone replacement therapy (HRT). Among the two therapeutic area segments, HRT is expected to register highest CAGR as compared to pain management during the forecast period. HRT is expected to gain popularity owing to increasing awareness across the world due to its various benefits associated with age-defying therapies and products to bettering individual health.

Get Full Report Now @ https://www.futuremarketinsights.com/checkout/978

Key market participants covered in the report include PharMEDium Services, LLC, Institutional Pharmacy Solutions, Cantrell Drug Company, and Triangle Compounding Pharmacies

Global Portable Oxygen Concentrators Market is Anticipated to Register a CAGR of 7.8% between 2016 and 2026

According to a latest report published by Future Market Insights titled “Portable Oxygen Concentrators Market: Global Industry Analysis and Opportunity Assessment, 2016–2026,” the global portable oxygen concentrators market is anticipated to register a CAGR of 7.8% between 2016 and 2026 in terms of value. 

Portable oxygen concentrators supply oxygen to patients suffering from respiratory diseases such as chronic obstructive pulmonary diseases. The concentrator separates nitrogen and oxygen from air in the environment and then supplies 95% pure oxygen to patients. POCs are easy to carry as they are smaller in size compared to stationary concentrators. Moreover, POCs are of great use to mountaineers and travellers in places where oxygen is inadequate. 

According to Future Market Insights, the global portable oxygen concentrators market is likely to witness substantial growth owing to increasing prevalence of chronic obstructive pulmonary diseases, growing consumer awareness for oxygen therapy devices, and a changing consumer lifestyle. Further, adoption of new technologies in medical devices, increasing government expenditure towards healthcare and medical devices development and production, and a rise in investment by companies manufacturing homecare products is likely to boost the growth of the global portable oxygen concentrators market during the forecast period (2016 – 2026). However, high product costs and stringent FDA regulations pertaining to medical devices are some of the factors likely to restrain the growth of the global portable oxygen concentrators market during the forecast period. 

Segmentation highlights

The global portable oxygen concentrators market has been segmented on the basis of Product into Continuous Flow Portable Oxygen Concentrator and Pulse Flow Portable Oxygen Concentrator; and on the basis of End User into Hospitals, Homecare, Ambulatory Surgical Centres, and Travel Agents.

  • The Pulse Flow Portable Oxygen Concentrator product segment is projected to be valued at US$ 1890.3 Mn by 2026, registering a CAGR of 9.0% over the forecast period
  • The Homecare end user segment is projected to be valued at US$ 1820.5 Mn by 2026 and is likely to witness a CAGR of 9.0% over the forecast period 

Request Sample Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-1061 

Regional market projections

The global portable oxygen concentrators market is segmented into the seven key regions of North America, Latin America, Western Europe, Eastern Europe, APEJ, MEA, and Japan. Growing geriatric population consequently increasing the requirement for homecare settings particularly in high income countries with increasing number of patients suffering from chronic obstructive pulmonary diseases is expected to result in significant growth of the North America portable oxygen concentrators market. The North America region is expected to report incremental opportunity of US$ 781.7 Mn between 2016 and 2026. Evolution of health insurance system is expected to contribute largely to the revenue generation potential and attractiveness of the Eastern Europe portable oxygen concentrators market. Rising adoption of portable oxygen concentrators in chronic obstructive pulmonary diseases patients for better care is expected to fuel revenue growth in the Japan portable oxygen concentrators market over the forecast period. High product cost of portable oxygen concentrators is expected to hamper sustainable adoption in the APEJ region. Lack of product awareness is expected to hamper market growth in the APEJ and MEA regions.

Request to View TOC @  https://www.futuremarketinsights.com/askus/rep-gb-1061

Vendor insights

The report profiles some of the top companies operating in the global portable oxygen concentrators market such as Koninklijke Philips N.V., Inogen Inc., Chart Industries Inc., Resmed Inc., Invacare Corporation, Drive DeVilbiss Healthcare, Precision Medical Inc., Besco Medical Co. Ltd., Oxus America, Inc. (Oxus), Foshan Keyhub Electronic Industries Co. Ltd., O2 Concepts LLC, and GCE Group. Key strategies adopted by leading market players in the global portable oxygen concentrators market include product approvals and commercialisation, efficient entry into markets in emerging countries, and adoption of latest innovative technologies in healthcare, thus strengthening regional proficiency and addressing customer needs effectively. New product launches, product innovation, and geographical expansion are anticipated to form the core of these strategies during the forecast period.

Laboratory Information Systems Market Research Report – Forecast to 2027

Laboratory Information Systems Market – Insights

The Global Laboratory Information Systems (LIS) is set to surge at CAGR of 7.3% during the forecast period (2016-2027), predicts Market Research Future (MRFR). There are several practice applications of a LIS that improve the day-to-day operations of a medical laboratory, along with prevention of medical errors.

A busy medical laboratory having many patients on a regular basis encounter difficulty in keeping all the patients’ information organized. Thus, a LIS system comes in handy, as it helps keep all this information organized, which is vitally important for a medical lab to run smoothly. Apart from this, rising integration of LIS and Electronic Health Record (EHR) and demand for quality and precision diagnosis are majorly supplementing the market growth globally. Moreover, increasing penetration of mobile applications in healthcare solutions coupled with growing popularity of cloud-based laboratory information system testifies for the market progress that has taken place in the past few years.

On the flip side, lack of skilled information technology (IT) professionals in the healthcare industry tames the flow of the progressing market. However, an array of opportunities stemming from emerging regions along with the consistently growing adoption of LIS are proof enough that the global market is en-route to brighter future prospects.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/852

Laboratory Information Systems Market – Key Players

The key players that are involved in Global Laboratory Information Systems market are Cerner Corporation, Recent Developments, Eclipsys Corporation, LabVantage Solutions Inc, LabWare Inc, McKesson Corporation, Medical Information Technology Inc., Merge Healthcare Inc, STARLIMS Corporation, Sunquest Corporation and Thermo Fisher Scientific Inc.

Industry Updates:

Nov 2014 Thermo Fisher launched a new ultracentrifuge which combines speed with safety and ergonomics, allowing researchers to easily protect samples while achieving reliable and consistent results.

Sept 2014 Cerner announced a strategic agreement with Intermountain Healthcare to provide clinical governance of solutions and workflow to be proposed for the Department of Defense’s Healthcare Management System Modernization (DHMSM) initiative.

Aug 2014 Cerner Corporation and Siemens AG signed a definitive agreement for Cerner to acquire the assets of Siemens’ health information technology business unit, Siemens Health Services, for $1.3 billion in cash. As part of the agreement, Cerner and Siemens will form a strategic alliance to bring new solutions to market that combine Cerner’s health IT leadership and Siemens’ strengths in medical devices and imaging services.

March 2014 LabVantage launched a new product known as LabVantage 7 Express for quality controlled smaller labs.

Laboratory Information Systems Market – Segments

Segmentation by Applications

Segmentation for Laboratory Information Systems market involves the following Applications such Clinical LIS Market, Drug Discovery LIS Market, Industrial LIS Market.

Segmentation by Components

Segmentation for Laboratory Information Systems market involves the following Components such as Software in LIS Market, Hardware in LIS Market, Services in LIS Market.

Segmentation by Delivery

Segmentation for Laboratory Information Systems market involves the following Delivery such as Web-based LIS Market, On-premise based LIS Market, Cloud-based LIS Market.

Laboratory Information Systems Market – Regional Analysis

Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

The North America dominated the global Laboratory Information Systems market. The adoption of cloud computing is expected to rise in the U.S. healthcare sector due to continuous pressure to lower cost for customized healthcare services. According to clauses of the HIPAA, the healthcare industry in the U.S. has to adopt new systems that support electronic medical records (EMR) and share data in an efficient and secure manner with other healthcare providers and government agencies. This will lead to higher adoption of cloud-based LIS, which allow laboratories to share real-time information with hospitals and patients. In terms of LIS usage, North American and Western European markets are witnessing penetration, due to early adoption of healthcare technologies.

Browse Complete 83 Pages Premium Research Report Enabled with Tables and Figures @

https://www.marketresearchfuture.com/reports/laboratory-information-systems-market-852

The European LIS market is expected to grow moderately, driven by higher incidence rate of diseases and increasing patient awareness about new technologies. In addition, various government initiatives also helped in promoting the usage of LIS. Increasing demand for better healthcare facilities and rising need for integrated healthcare systems in the two regions are some of the key driving factors for these markets.

The LIS market is expected to grow in Asia-Pacific (APAC) due to increase in the incidences of diseases. Asia and Latin America are among the fastest growing markets for LIS; rising investments from healthcare IT players and government initiatives are some of the key driving factors for LIS in these regions. Many international LIS firms have started investing in developing regions of the world, such as Asia and Latin America, in order to increase their presence in high potential markets.

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued….

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact: 

Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: 
sumit.choudhari@marketresearchfuture.in

Continuous Glucose Monitoring Systems Market to Display Positive Growth at a CAGR of 12.1%

According to a recent market report published by Future Market Insights, titled “Continuous Glucose Monitoring Systems Market – Global Industry Analysis and Opportunity Assessment, 2015–2020”, the global continuous glucose monitoring systems market was valued at US$ 445.8 Mn in 2015 and is expected to register a CAGR of 12.1% from 2015 to 2020.

Continuous glucose monitoring systems are adopted by many end-users including household, and hospitals and diagnostics centers. There is an increase in the usage of continuous glucose monitoring systems components in hospitals and diagnostic centers due to an increase in the demand for sensor.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-694

Currently, companies are focusing on continuous development and the introduction of innovative continuous glucose monitoring system devices to receive FDA approval for various brands, which has led to high competitiveness in the market. Scientists are conducting research and testing continuous glucose monitoring systems to provide effective systems and aid better management of diabetes.  Thus, there is scope for the introduction of new and advanced continuous glucose monitoring systems in the near future. Market players operating in the continuous glucose monitoring systems market are focused towards the integration of advanced technologies in products in order to offer variations and trends in the type of blood glucose level display.

On the other hand, the high cost of continuous glucose monitoring systems acts as a restrain for the growth of the market as treatment with continuous glucose monitoring systems costs around US$ 4,930 to US$ 7,120 per person. This makes it unaffordable for a large portion of the global population. For instance, glucose monitors used in continuous glucose monitoring systems cost between US$ 1,000 and US$ 1,400, while sensors cost between US$ 35 and US$ 100 apiece. Besides this, sensors have a very short lifespan – around 3 to 7 days – since they are prone to biofouling, which affects the accuracy of the continuous glucose monitoring systems.

Due to the lack of accuracy in the readings of glucose levels in critical cases, continuous glucose monitors are incapable of preventing severe hypoglycemia stage, in which the glucose level in the body is extremely low. For instance, continuous glucose monitoring systems are up to 21% less accurate when compared with actual plasma glucose values and this percentage increases when there is a rapid rise and fall in plasma glucose. According to the results of studies, it is estimated that the probable reason behind this problem is the real-time performance delay of continuous glucose monitoring systems.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-694

The global continuous glucose monitoring systems market has been categorized on the basis of component into transmitter & monitor, sensor and insulin pump. On the basis of end-use, the continuous glucose monitoring systems market has segmented into household and hospitals and diagnostics centers. In terms of revenue, the household segment dominated the global continuous glucose monitoring systems market. Hospital and diagnostics centers segments are anticipated to expand at the fastest CAGRs over the forecast period.

This continuous glucose monitoring systems report also covers trends that drive each segment and offers analysis & insights regarding the potential of the continuous glucose monitoring systems market in regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East & Africa, and Japan. Among these regions, the APEJ continuous glucose monitoring systems market is projected to exhibit relatively high growth in the global continuous glucose monitoring systems market with a CAGR of 16% over the forecast period. Revenue from the continuous glucose monitoring systems market in APEJ accounted for over 7% of the global continuous glucose monitoring systems market revenue in 2015. Providers of continuous glucose monitoring systems can focus on expanding across several countries in APEJ such as India and China.

Some of the key competitors in the continuous glucose monitoring systems market include Abbott, Medtronic, Dexcom, Animas, Roche, Bayer, Glysens and Ypsomed. These key players are constantly focusing on product innovation and geographical expansion to sustain their market presence and increase revenue generation by developing various types of devices and delivering outstanding offerings to several end-users.

Get Full Report Now @ https://www.futuremarketinsights.com/checkout/694

Page 1 of 69

Powered by WordPress & Theme by Anders Norén